Patent · US Active

Selective histone deactylase 6 inhibitors

US9409858B2 · kind B2 · utility

6Cited by

0References

22Claims

0Family size

Assignees

H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. · US
BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS · US

Inventors

Eduardo M. Sotomayor · Tampa, US
Joel Bergman · Chicago, US
Alan P. Kozikowski · Princeton, US
Karrune V. Woan · Gainesville, US
Alejandro V. Villagra · Tampa, US

Key dates

Filing date	Mar 7, 2013
Grant date	Aug 9, 2016
Priority date	—
Expiry date	Mar 7, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula (I). Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.